BR0108154A - Derivados indol-3-ila - Google Patents

Derivados indol-3-ila

Info

Publication number
BR0108154A
BR0108154A BR0108154-3A BR0108154A BR0108154A BR 0108154 A BR0108154 A BR 0108154A BR 0108154 A BR0108154 A BR 0108154A BR 0108154 A BR0108154 A BR 0108154A
Authority
BR
Brazil
Prior art keywords
derivatives
indol
disease
ila
angioplasty
Prior art date
Application number
BR0108154-3A
Other languages
English (en)
Inventor
Simon Goodman
Rudolf Gottschlich
Matthias Wiesner
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0108154A publication Critical patent/BR0108154A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

"DERIVADOS INDOL-3-ILA". Derivados 3-il-indol de fórmula geral I onde A, B, X, R^ 1^,R^ 2^,R^ 3^,R^ 4^,R^ 5^,n e m são como definidos na reivindicação 1 e seus sais ou solvatos fisiologicamente aceitáveis são inibidores de integrina e podem ser empregados para o combate de tromboses, infarto cardíaco, doenças cardíacas coronárias, arteriosclerose, inflamações, artrite reumática, doença macular degenerativa, retinopatia diabética, infecções e restenose após angioplastia ou em processos patológicos mantidos ou propagados por angiogênese.
BR0108154-3A 2000-02-11 2001-01-05 Derivados indol-3-ila BR0108154A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10006139A DE10006139A1 (de) 2000-02-11 2000-02-11 Indol-3-yl-Derivate
PCT/EP2001/000084 WO2001058893A2 (de) 2000-02-11 2001-01-05 Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren

Publications (1)

Publication Number Publication Date
BR0108154A true BR0108154A (pt) 2003-01-21

Family

ID=7630611

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108154-3A BR0108154A (pt) 2000-02-11 2001-01-05 Derivados indol-3-ila

Country Status (27)

Country Link
US (1) US6743810B2 (pt)
EP (1) EP1254133B9 (pt)
JP (1) JP4938194B2 (pt)
KR (1) KR20020073585A (pt)
CN (1) CN1214026C (pt)
AR (1) AR027398A1 (pt)
AT (1) ATE293620T1 (pt)
AU (2) AU3166401A (pt)
BR (1) BR0108154A (pt)
CA (1) CA2399813C (pt)
CO (1) CO5261548A1 (pt)
CZ (1) CZ20022616A3 (pt)
DE (2) DE10006139A1 (pt)
EC (1) ECSP013923A (pt)
ES (1) ES2240400T3 (pt)
HU (1) HUP0302671A2 (pt)
IL (1) IL151154A0 (pt)
MX (1) MXPA02007732A (pt)
NO (1) NO20023770L (pt)
NZ (1) NZ521260A (pt)
PE (1) PE20011125A1 (pt)
PL (1) PL356427A1 (pt)
PT (1) PT1254133E (pt)
RU (1) RU2257380C2 (pt)
SK (1) SK11152002A3 (pt)
WO (1) WO2001058893A2 (pt)
ZA (1) ZA200207273B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063790A1 (en) * 1996-05-31 2004-04-01 The Scripps Research Institute Methods for inhibition of angiogenesis
US20040138284A1 (en) * 2000-02-11 2004-07-15 Matthias Wiesner Indol-3-yl derivatives
AU2001288485A1 (en) * 2000-08-29 2002-03-13 Balekudru Devadas Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
DK1381382T3 (da) * 2000-11-01 2009-02-02 Merck Patent Gmbh Fremgangsmåder og præparater til behandling af öjensygdomme
GB0028367D0 (en) * 2000-11-21 2001-01-03 Celltech Chiroscience Ltd Chemical compounds
NZ539682A (en) * 2001-01-29 2006-03-31 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
ES2243744T3 (es) * 2001-08-01 2005-12-01 Merck Patent Gmbh Inhibidores de integrina para el tratamiento de enfermedades de los ojos.
WO2003068253A1 (en) * 2002-02-14 2003-08-21 Merck Patent Gmbh Methods and compositions for the treatment of eye diseases
WO2004020434A1 (ja) * 2002-08-30 2004-03-11 Eisai Co., Ltd. 含窒素芳香環誘導体
WO2004092130A2 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders
EP1620088A4 (en) * 2003-04-28 2007-08-29 Bayer Pharmaceuticals Corp ACETIC INDOLE ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS
US7211588B2 (en) 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
DE10337863A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Verwendung von Chromen-4-on-Derivaten
JP4912881B2 (ja) * 2003-10-01 2012-04-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗線維症薬としてのαｖβ３及びαｖβ６インテグリンアンタゴニスト
JP2007536344A (ja) * 2004-05-04 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ 新規のインドール誘導体
WO2006053342A2 (en) * 2004-11-12 2006-05-18 Osi Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
EP1676834A1 (en) * 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
WO2007024294A2 (en) * 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
CN102335168B (zh) * 2011-10-25 2014-04-02 合肥博太医药生物技术发展有限公司 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗骨质疏松药物中的应用
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
MX369646B (es) 2014-08-18 2019-11-15 Eisai R&D Man Co Ltd Sal de derivado de piridina monociclico y su cristal.
AU2016237222B2 (en) 2015-03-25 2021-04-29 Eisai R&D Management Co., Ltd. Therapeutic agent for bile duct cancer
CA3001969C (en) 2015-12-17 2023-10-03 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
JPWO2019189241A1 (ja) 2018-03-28 2021-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT290523B (de) * 1962-01-05 1971-06-11 Merck & Co Inc Verfahren zur Herstellung neuer α-(3-Indolyl)-carbonsäuren
GB1148909A (en) * 1965-04-19 1969-04-16 Sumitomo Chemical Co Process for production of novel phenylhydrazone and phenylhydrazine derivatives
US4824850A (en) * 1982-05-18 1989-04-25 University Of Florida Brain-specific drug delivery
US4983615A (en) * 1989-06-28 1991-01-08 Hoechst-Roussel Pharmaceuticals Inc. Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
IT1244548B (it) * 1991-02-06 1994-07-15 Poli Ind Chimica Spa Derivati della 5-oxo-l-prolina e loro applicazioni farmaceutiche
GB9225141D0 (en) * 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
CA2251017A1 (en) 1996-04-10 1997-10-16 Mark E. Duggan .alpha.v.beta.3 antagonists
ES2188970T3 (es) * 1996-08-27 2003-07-01 Wyeth Corp 4-aminoetoxiindoles, como agonistas d2 de dopamina y como ligandos de los receptores 5ht1a.
AU1687699A (en) * 1997-12-25 1999-07-19 Yamanouchi Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives
JP5627160B2 (ja) * 1998-02-23 2014-11-19 サウス、アラバマ、メディカル、サイエンス、ファウンデーションＳｏｕｔｈ Ａｌａｂａｍａ Ｍｅｄｉｃａｌ Ｓｃｉｅｎｃｅ Ｆｏｕｎｄａｔｉｏｎ 医薬として用いるインドール−３−プロピオン酸、並びにそれらの塩およびエステル
PL343007A1 (en) * 1998-02-25 2001-07-30 Genetics Inst Inhibitors of phospholipase enzymes
JP2002510675A (ja) * 1998-04-08 2002-04-09 アメリカン・ホーム・プロダクツ・コーポレイション うつ病治療用のｎ−アリールオキシエチル−インドリル−アルキルアミン（５−ｈｔ１ａ受容体活性薬）
CN1160332C (zh) * 1998-04-08 2004-08-04 惠氏公司 用于治疗抑郁症的n-芳氧基乙基胺衍生物
JP4425699B2 (ja) * 2004-05-17 2010-03-03 川崎重工業株式会社 小型滑走艇

Also Published As

Publication number Publication date
NO20023770D0 (no) 2002-08-09
CO5261548A1 (es) 2003-03-31
ZA200207273B (en) 2003-12-10
ECSP013923A (es) 2002-09-27
PT1254133E (pt) 2005-09-30
NO20023770L (no) 2002-08-09
PE20011125A1 (es) 2001-11-07
AU3166401A (en) 2001-08-20
MXPA02007732A (es) 2002-10-11
EP1254133A2 (de) 2002-11-06
CN1214026C (zh) 2005-08-10
ES2240400T3 (es) 2005-10-16
NZ521260A (en) 2004-02-27
ATE293620T1 (de) 2005-05-15
RU2257380C2 (ru) 2005-07-27
IL151154A0 (en) 2003-04-10
JP4938194B2 (ja) 2012-05-23
SK11152002A3 (sk) 2003-01-09
CZ20022616A3 (cs) 2002-10-16
DE10006139A1 (de) 2001-08-16
KR20020073585A (ko) 2002-09-27
CA2399813C (en) 2010-03-09
PL356427A1 (en) 2004-06-28
AR027398A1 (es) 2003-03-26
EP1254133B1 (de) 2005-04-20
RU2002123332A (ru) 2004-01-10
CN1398264A (zh) 2003-02-19
WO2001058893A3 (de) 2002-04-18
AU2001231664C1 (en) 2006-10-05
JP2003530319A (ja) 2003-10-14
HUP0302671A2 (hu) 2003-12-29
HK1051863A1 (en) 2003-08-22
EP1254133B9 (de) 2005-09-07
US6743810B2 (en) 2004-06-01
DE50105955D1 (de) 2005-05-25
WO2001058893A2 (de) 2001-08-16
US20030045728A1 (en) 2003-03-06
CA2399813A1 (en) 2001-08-16
AU2001231664B2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
WO2001058893A3 (de) Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren
BRPI0508876A (pt) pró medicamentos de agentes antivirais de piperazina e piperidina substituìda
ATE240940T1 (de) Arylsulfonanilid-harnstoffe
BR0313732A (pt) Compostos de pirimido tendo atividade antiproliferativa
BR0008310A (pt) Derivados de alfa-alanina
BR0014078A (pt) Inibidores de fator xa
DE602006006138D1 (de) Schaumbildendes, lösliches, kosmetisches Produkt
BR0314186A (pt) Derivados de pirimidinona como agentes terapêuticos contra processos inflamatórios, isquêmicos e remodeladores, agudos e crÈnicos
BRPI0409716A (pt) derivados de 2-acilamino-4-feniltiazol, seu preparo e sua aplicação em terapêutica
BR9710737A (pt) Pentafluorobenzenosulfonamidas e análogos.
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
UY26926A1 (es) Derivados de la quinolina y quinazolina
UY27300A1 (es) Nuevos derivados de quinolina
BRPI0518192B8 (pt) derivados de 3-arilamino piridina, seu uso e seu processo de fabricação, e composição farmacêutica
BRPI0517999A (pt) derivados de tetraidropirano como antidiabéticos
EP1508570A4 (en) NEW PHYSIOLOGICAL ACTIVE SUBSTANCES
BR0116202A (pt) Derivados de uréia e uretano como inibidores de integrinas
BR0115045A (pt) Compostos, processo para sua preparação, composição farmacêutica que compreende os mesmos, sua utilização, processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
DE60008935D1 (de) Pyridinsulfonylharnstoffderivate mit herbizider wirkung
BR0308195A (pt) Derivados de isoquinolina
TR200102008T2 (tr) Serebral işemi profilaksı ve tedavisi için piridin türevlerinin kullanımı.
BR0108607A (pt) Derivados de aminossulfonilbifenila
BR0113344A (pt) Derivados de aza amino ácido (inibidores 15 de fator xa)
BR9805437A (pt) Derivados de benzocicloalquenos heterocìclicos, processo para fabricação de derivados de benzocicloalquenos heterocìclicos e uso de derivados de benzocicloalquenos heterocìclicos.
BR0112655A (pt) Derivados de pirrolidino como inibidores de metaloproteases

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009